<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387164</url>
  </required_header>
  <id_info>
    <org_study_id>DiAPREV/2014</org_study_id>
    <nct_id>NCT02387164</nct_id>
  </id_info>
  <brief_title>Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies</brief_title>
  <acronym>DiAPREV-IT2</acronym>
  <official_title>Double-blind, Investigator-initiated Study to Determine the Effect of Alum-GAD (Diamyd) in Combination With Vitamin D3 on the Progression to Type 1 Diabetes in Children With Multiple Islet Autoantibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if immune-tolerance with Alum-formulated GAD
      (Diamyd), in combination with high dose Vitamin D3, may delay or stop the autoimmune process
      leading to clinical type 1 diabetes in non-diabetic children with ongoing beta-cell
      autoimmunity as indicated by positive islet autoantibodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate if immune-tolerance with Alum-formulated
      GAD (Diamyd), combined with high dose Vitamin D3, may delay or stop the autoimmune process
      leading to clinical type 1 diabetes (diagnosed according to American Diabetes Association
      criteria) in non-diabetic 4-17.99 year old children with ongoing beta-cell autoimmunity as
      indicated by positive islet autoantibodies.

      The secondary objective is to demonstrate that treatment with Diamyd is safe in children at
      risk for type 1 diabetes.

      The children will be followed for 5 years in the study. Primary endpoint is proportion of
      subjects diagnosed with type 1 diabetes in each treatment arm. Secondary endpoints are 1)
      safety, 2) change in metabolic status from normal to impaired glucose metabolism in the group
      of children with normal glucose metabolism at baseline screening.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type 1 diabetes</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of subjects diagnosed with type 1 diabetes according to ADA criteria in each study arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impaired glucose metabolism</measure>
    <time_frame>During 5 year follow-up</time_frame>
    <description>Change in metabolic status from normal to impaired glucose metabolism during follow-up in the group of children with normal glucose metabolism at baseline screening.
Impaired glucose metabolism is defined as a) fasting plasma glucose 6.1 mmol/L or more, b) maximum plasma glucose 30, 60, 90 min during oral glucose tolerance test (OGTT) 11.1 mmol/L or more, c) 120 min plasma glucose on OGTT 7.8 mmol/L or more, d) HbA1c 39 mmol/L or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by occurrence of adverse events</measure>
    <time_frame>5 years follow-up</time_frame>
    <description>Evaluation of safety of Diamyd and high dose Vitamin D3 in non-diabetic children as measured by occurrence of adverse events, injection site reactions, abnormal laboratory parameters or physical exam.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Prediabetic State</condition>
  <arm_group>
    <arm_group_label>Alum-GAD, Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses à 20 microgram of subcutaneous alum-GAD (Diamyd), 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Vitamin D3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two doses of subcutaneous placebo, 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alum-GAD</intervention_name>
    <description>Two doses à 20 microgram 30 days apart subcutaneously administrated</description>
    <arm_group_label>Alum-GAD, Vitamin D3</arm_group_label>
    <other_name>Diamyd</other_name>
    <other_name>GAD-Alum</other_name>
    <other_name>Alumformulated GAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>2000 Units (IE) (50 microgram) vitamin D3 daily</description>
    <arm_group_label>Alum-GAD, Vitamin D3</arm_group_label>
    <arm_group_label>Placebo, Vitamin D3</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 4-17.99 years of age with positive autoantibodies to glutamate decarboxylase
             (GADA) and at least one additional type 1 diabetes associated autoantibody (to
             insulinoma associated protein 2 (IA-2A), Zinktransporter 8 (ZnT8R/Q/WA) or insulin
             (IAA)).

          -  Written informed consent from the child and the childs legal representative(s).

        Exclusion Criteria:

          1. Ongoing treatment with immunosuppressant therapy.

          2. Diabetes.

          3. Treatment with any oral or injected anti-diabetic medications

          4. Significantly abnormal hematology results at screening.

          5. Clinically significant history of acute reaction to vaccines or other drugs

          6. Treatment with any vaccine within one month prior to the first dose of the study drug
             or planned treatment with vaccine up to three months after the last injection with the
             study drug.

          7. A history of epilepsy, serious head trauma or cerebrovascular accident, or Clinical
             features of continuous motor unit activity in proximal muscles

          8. Participation in other Clinical trials with a new chemical entity within the previous
             3 months.

          9. History of hypercalcemia.

         10. Unwilling to abstain from other medication with Vitamin D during the study period.

         11. Significant illness within 2 weeks prior to first dosing.

         12. Known Human Immuno Deficiency Virus infection or hepatitis.

         13. Presence of associated serious disease or condition.

         14. Diabetes-protective Human Leucocyte Antigen (HLA) DQ6.

         15. Females who are lactating or pregnant.

         16. Males or females not willing to use adequate contraception, if sexually active, until
             1 year after the last Diamyd administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Elding Larsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center, Pediatric Endocrinology, Jan Waldenströms gata 35, 60:11</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.ludc.med.lu.se/research-units/diabetes-and-celiac-disease/research-projects/diabetes-prevention-immune-tolerance/</url>
    <description>Link to the description of the first DiAPREV-IT study, that have included 50 children and is still ongoing</description>
  </link>
  <reference>
    <citation>Elding Larsson H, Larsson C, Lernmark Å; DiAPREV-IT study group. Baseline heterogeneity in glucose metabolism marks the risk for type 1 diabetes and complicates secondary prevention. Acta Diabetol. 2015 Jun;52(3):473-81. doi: 10.1007/s00592-014-0680-1. Epub 2014 Nov 8.</citation>
    <PMID>25381193</PMID>
  </reference>
  <reference>
    <citation>Andersson C, Carlsson A, Cilio C, Cedervall E, Ivarsson SA, Jonsdottir B, Jönsson B, Larsson K, Neiderud J, Lernmark A, Elding Larsson H; DiAPREV-IT Study Group. Glucose tolerance and beta-cell function in islet autoantibody-positive children recruited to a secondary prevention study. Pediatr Diabetes. 2013 Aug;14(5):341-9. doi: 10.1111/pedi.12023. Epub 2013 Mar 8.</citation>
    <PMID>23469940</PMID>
  </reference>
  <reference>
    <citation>Ludvigsson J, Krisky D, Casas R, Battelino T, Castaño L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, Veeze HJ, Palmer J, Samuelsson U, Elding Larsson H, Åman J, Kärdell G, Neiderud Helsingborg J, Lundström G, Albinsson E, Carlsson A, Nordvall M, Fors H, Arvidsson CG, Edvardson S, Hanås R, Larsson K, Rathsman B, Forsgren H, Desaix H, Forsander G, Nilsson NÖ, Åkesson CG, Keskinen P, Veijola R, Talvitie T, Raile K, Kapellen T, Burger W, Neu A, Engelsberger I, Heidtmann B, Bechtold S, Leslie D, Chiarelli F, Cicognani A, Chiumello G, Cerutti F, Zuccotti GV, Gomez Gila A, Rica I, Barrio R, Clemente M, López Garcia MJ, Rodriguez M, Gonzalez I, Lopez JP, Oyarzabal M, Reeser HM, Nuboer R, Stouthart P, Bratina N, Bratanic N, de Kerdanet M, Weill J, Ser N, Barat P, Bertrand AM, Carel JC, Reynaud R, Coutant R, Baron S. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med. 2012 Feb 2;366(5):433-42. doi: 10.1056/NEJMoa1107096.</citation>
    <PMID>22296077</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Islet autoantibodies</keyword>
  <keyword>glutamate decarboxylase autoantibodies (GADA)</keyword>
  <keyword>Immune tolerance</keyword>
  <keyword>Prediabetes</keyword>
  <keyword>Glucose tolerance</keyword>
  <keyword>glutamate decarboxylase</keyword>
  <keyword>Prevention</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Aluminum sulfate</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

